Loading...
•
Jun 30
Glaukos Q2 2025 Earnings Report
Glaukos reported record net sales and improved profitability in the second quarter of 2025, driven by strong growth in its Glaucoma segment, particularly in the U.S.
Key Takeaways
Glaukos Corporation achieved record net sales of $124.1 million in Q2 2025, a 30% increase year-over-year. The company significantly reduced its net loss to $19.7 million from $50.5 million in the prior year, and improved its GAAP and non-GAAP gross margins. This performance was primarily fueled by a 36% increase in Glaucoma net sales, with U.S. Glaucoma sales surging by 45%.
Record net sales reached $124.1 million in Q2 2025, marking a 30% year-over-year increase.
Glaucoma segment sales hit a record $103.5 million, growing 36% compared to the same period last year.
U.S. Glaucoma net sales demonstrated robust growth, increasing 45% year-over-year to $72.3 million.
Net loss significantly narrowed to $19.7 million, or ($0.34) per diluted share, a substantial improvement from ($1.00) per diluted share in Q2 2024.
Glaukos
Glaukos
Glaukos Revenue by Segment
Glaukos Revenue by Geographic Location
Revenue by Segment
Glaucoma Revenue
CapyFin.comRevenue by Geographic Location
U.S. Glaucoma Revenue
CapyFin.comInternational Glaucoma Revenue
CapyFin.com Forward Guidance
Glaukos raised its full-year 2025 net sales guidance, reflecting confidence in continued growth.
Positive Outlook
- Raised 2025 net sales guidance to a range of $480 million to $486 million.
- The updated guidance is an increase from the previous range of $475 million to $485 million.
- Reflects sustained growth acceleration and successful global execution of strategic plans.
- Indicates positive outlook on the robust pipeline of novel, dropless platform technologies.
- Suggests continued efforts to advance the standard of care and improve patient outcomes.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text.
- Potential impact of general macroeconomic conditions, including foreign currency fluctuations, could affect future results.
- Ability to secure or maintain adequate coverage or reimbursement by third-party payors for products remains a factor.
- The lengthy and expensive clinical trial process and regulatory approval uncertainties could impact pipeline advancement.
- Risk of recalls or serious safety issues with products, and the uncertainty of patient outcomes, are inherent.